PML risk with Natalizumab in MS identified with new test

[MSUK]

A new test seems to be able to stratify patients at risk for progressive multifocal leukoencephalopathy (PML) while receiving the multiple sclerosis (MS) drug natalizumab more effectively than anything available at present.

The test is based on observations that patients who develop PML appear to have very low levels of L-selectin (CD62L) on CD4+ T cells in the months or years before they develop the condition..... Read More - http://www.ms-uk.org/tysabri